Skip to main content

Advertisement

Table 3 Associations of PITX2 DNA methylation (mPITX2) with clinicopathological parameters of PCa patients from the training cohort (n = 498)

From: PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

  Patients (n) Median mPITX2 (%) mPITX2 low mPITX2 high p value
All patients 498 (100 %) 32.9    
Mean/median follow-up (months) 22/16     
Age (years)      0.001a
 ≤60 224 (45.0 %) 31.0 128 (57.1 %) 96 (42.9 %)  
 >60 274 (55.0 %) 35.2 135 (49.1 %) 140 (50.9 %)  
 Unknown 0 (0.0 %)     
T category      0.043a
 pT1/2 188 (37.8 %) 25.7 137 (70.3 %) 58 (29.7 %)  
 pT3/4 293 (58.8 %) 37.5 126 (41.4 %) 178 (58.6 %)  
 Unknown 17 (3.4 %)     
ISUP Gleason grading group      <0.001b
 1 (<7) 45 (9 %) 28.0 31 (68.9 %) 14 (31.1 %)  
 2 (3 + 4) 147 (29.5 %) 28.6 95 (64.2 %) 53 (35.8 %)  
 3 (4 + 3) 101 (20.3 %) 31.5 55 (54.5 %) 46 (45.5 %)  
 4 (=8) 64 (12.9 %) 34.1 33 (51.6 %) 31 (48.4 %)  
 5 (>8) 141 (28.3 %) 41.0 49 (34.8 %) 92 (65.2 %)  
 Unknown 0 (0.0 %)     
Surgical margin      <0.001a
 R0 318 (63.9 %) 30.8 180 (56.8 %) 137 (43.2 %)  
 R1 152 (30.5 %) 37.0 68 (44.7 %) 84 (55.3 %)  
 Unknown 28 (5.6 %)     
Nodal status      0.19a
 pN0 349 (70.1 %) 32.3 184 (53.0 %) 163 (47.0 %)  
 pN1 79 (15.8 %) 36.6 32 (40.5 %) 47 (49.5 %)  
 Unknown 70 (14.1 %)     
Pre-surgical PSA (ng/ml)      0.36b
 0–4 53 (10.6 %) 29.5 31 (58.5 %) 122 (41.5 %)  
 4–10 286 (57.5 %) 32.9 150 (52.4 %) 136 (47.6 %)  
 >10 156 (31.3 %) 34.3 79 (50.3 %) 78 (49.7 %)  
 Unknown 3 (0.6 %)     
ERG fusionc      <0.001a
 Negative 178 (35.8 %) 28.0 122 (62.9 %) 66 (37.1 %)  
 Positive 152 (30.5 %) 37.2 69 (45.4 %) 83 (54.6 %)  
 Unknown 168 (33.7 %)     
AR score      0.15a
 Negative 246 (49.4 %) 30.6 140 (56.9 %) 106 (43.1 %)  
 Positive 84 (16.9 %) 34.6 41 (48.8 %) 43 (51.2 %)  
 Unknown 186 (33.7 %)     
  1. mPITX2 in the validation cohort is described elsewhere [30]. mPITX2 was dichotomized by the respective optimized cutoff into mPITX2 low vs. mPITX2 high
  2. aWilcoxon-Mann-Whitney test
  3. bKruskal-Wallis test
  4. cERG fusion status as adopted from The Cancer Genome Atlas Research Network (2015) [27]